Cancer Research: A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models (Houghton, Kurmasheva)

February 19, 2021

Shaun D. Fontaine, Gary W. Ashley, Peter J. Houghton, Raushan T. Kurmasheva, Morgan Diolaiti, Alan Ashworth, Cody J. Peer, Ryan Nguyen, William D. Figg Sr., Denis R. Beckford-Vera, and Daniel V. Santi Abstract PARP inhibitors are approved for the treatment of cancers with BRCA1 or BRCA2 defects. In this study, we prepared and characterized a […]

Clinical Cancer Research: The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models

February 15, 2021

Nathan M. Kendsersky, Jarrett M Lindsay, Edward A. Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen Erickson, Eric J Earley, Yaël P. Mossé, Daniel Martinez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Gorlick, Raushan T. Kurmasheva, Peter J. Houghton and John M. Maris Abstract Purpose: Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many pediatric cancers. Here, we investigate the […]

Oncogene: MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma

February 9, 2021

Xin-Yu Ke, Ye Chen, Valarie Yu-Yan Tham, Ruby Yu-Tong Lin, Pushkar Dakle, Kassoum Nacro, Mark Edward Puhaindran, Peter Houghton, Angela Pang, Victor Kwanmin Lee, Ling-Wen Ding, Sigal Gery, Jeffrey Hill, Leilei Chen, Liang Xu & H. Phillip Koeffler Abstract Soft tissue sarcoma (STS) is a heterogeneous disease that arises from connective tissues. Clinical outcomes of patients […]

Nature Communications: Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma (Ignatius, Houghton, Chen)

January 14, 2021

Silvia Pomella, Prethish Sreenivas, Berkley E. Gryder, Long Wang, David Milewski, Matteo Cassandri, Kunal Baxi, Nicole R. Hensch, Elena Carcarino, Young Song, Hsien-Chao Chou, Marielle E. Yohe, Benjamin Z. Stanton, Bruno Amadio, Ignazio Caruana, Cristiano De Stefanis, Rita De Vito, Franco Locatelli, Yidong Chen, Eleanor Y. Chen, Peter Houghton, Javed Khan, Rossella Rota & Myron S. […]

Cell Reports: GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth

November 3, 2020

Fuchun Zhou (1), David J.Elzi (1, 2), Panneerselvam Jayabal(1), Xiuye Ma(1), Yu-Chiao Chiu (1) Yidong Chen 1,3,4) Barron Blackman(1) Susan T.Weintraub (4, 5) Peter J.Houghton 1,4,6) Yuzuru Shiio (1,4,5,7) Highlights The autocrine signaling mediated by GDF6 maintains Ewing sarcoma growth The GDF6 prodomain is a ligand for CD99, a widely used marker for Ewing sarcoma […]

ECancer Interview: Prospective validation of single mouse testing by the paediatric preclinical testing consortium (Houghton)

October 24, 2020

Dr. Peter Houghton speaks to ecancer about the prospective validation of single mouse testing by the pediatric preclinical testing consortium; a study that was presented at ENA 2020 this year. Dr. Houghton initially explains the rationale behind this study and talks about how it was tested that using a single mouse for studying drug efficacy [...]

MedicalXpress – One Mouse at a Time: a New Approach to Testing Potential Drugs for Children’s Cancers (Houghton, Kurmasheva, PPTC)

October 22, 2020

by European Organisation for Research and Treatment of Cancer A team of researchers in the US and Australia have developed a way of testing potential drugs for children’s cancers so as to take account of the wide genetic diversity of these diseases. In new research to be presented at the 32nd EORTC-NCI-AACR Symposium on Molecular […]

Pediatric Blood & Cancer: Radiation therapy and molecular‐targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges (Houghton)

October 14, 2020

Radiation therapy and molecular‐targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges Ralph Vatner, Charles D. James, Vythialingam Sathiaseelan, Kathryn M. Bondra, John A. Kalapurakal, Peter J. Houghton Abstract Despite radiation therapy (RT) being an integral part of the treatment of most pediatric cancers and the recent discovery of novel […]

Nucleic Acids Research: “PCAT: an Integrated Portal for Genomic and Preclinical Testing Data of Pediatric Cancer Patient-Derived Xenograft Models” in Oxford Academic (multiple faculty and researchers)

September 8, 2020

Juechen Yang, Qilin Li, Nighat Noureen (Greehey CCRI, Zheng Lab), Yanbing Fang, Raushan Kurmasheva (Greehey CCRI, Kurmasheva Lab), Peter J Houghton (Greehey CCRI, Houghton Lab), Xiaojing Wang (Greehey CCRI, Wang Lab), Siyuan Zheng (Greehey CCRI, Zheng Lab) Nucleic Acids Research, gkaa698, https://doi.org/10.1093/nar/gkaa698 Published:  18 August 2020 Abstract Although cancer is the leading cause of disease-related mortality in […]

Physician’s Weekly: PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.

August 20, 2020

Although cancer is the leading cause of disease-related mortality in children, the relative rarity of pediatric cancers poses a significant challenge for developing novel therapeutics to further improve prognosis. Patient-derived xenograft (PDX) models, which are usually developed from high-risk tumors, are a useful platform to study molecular driver events, identify biomarkers and prioritize therapeutic agents.